Medical condition
Igan
Igan is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- budesonide (BUDENOFALK) Alimentary tract and metabolism (A07)
- sparsentan (FILSPARI) Cardiovascular system (C09)
- denosumab (CORORA) Musculo-skeletal system (M05)
- durvalumab (IMFINZI) Antineoplastic and immunomodulating agents (L01)
- denosumab-bbdz (JUBBONTI)
- belimumab (BENLYSTA) Antineoplastic and immunomodulating agents (L04)
- atezolizumab (TECENTRIQ) Antineoplastic and immunomodulating agents (L01)
- avelumab (BAVENCIO) Antineoplastic and immunomodulating agents (L01)
- cosibelimab-ipdl (UNLOXCYT)
- enfortumab vedotin (PADCEV) Antineoplastic and immunomodulating agents (L01)
- sugemalimab (CEJEMLY) Antineoplastic and immunomodulating agents (L01)
- envafolimab
Latest Igan news
Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN
This week, the biotech sector saw a wave of regulatory and business development activity: PHG and KMDA won FDA approvals, FULC halted its pociredir program, RMD closed the Noctrix acquisition, and NVS posted positive data in IgAN. We break down what each event means for pharma teams and investors.
Kardigan's IPO Plans: Fueling the Next Wave of Cardiovascular Drug Development
Cardiovascular drug developer Kardigan is gearing up for an IPO on the Nasdaq Global Market to finance the late-stage development of its pipeline, including danicamtiv for genetic dilated cardiomyopathy. This move signals a potential uptick in biotech IPOs as the market becomes more discerning.